Sanofi invests $425 million in flu vaccine manufacturing site
Newly licensed US facility to increase availability of company's influenza vaccine
The FDA Center for Biologics Evaluation and Research has granted approval to Sanofi Pasteur, the vaccines global business unit of Sanofi, for an additional influenza manufacturing facility in Swiftwater, PA.
The newly completed $425 million investment in the site further expands production and distribution of Sanofi's Fluzone High-Dose Quadrivalent for the upcoming 2021-2022 influenza season in the US, and will also create up to 200 additional manufacturing jobs. Commercialization activities for this specific market have commenced, and there are plans to support other countries in the future, the company says.
"We are experiencing fast-growing demand for our vaccine in the US and globally, given the 10 years of data demonstrating protection from flu and its related complications," says Elaine O'Hara, head of North America commercial operations for Sanofi Pasteur. "Our new facility will complement our existing capacities to produce enough high-dose vaccine for all people 65 and older in as many countries as possible this flu season and beyond, supporting the needs of healthcare providers and patients."
